Drug testing at cycling's premier event, the Tour de France, has come under scrutiny due to a series of night-time anti-doping tests conducted on prominent athletes. On Saturday, both Tadej Pogacar, the yellow jersey leader from Slovenia, and his main rival, Jonas Vingegaard, faced testing in the middle of the night. Vingegaard subsequently crashed out of the race, leading to speculation that his disrupted sleep may have played a role.

Reports indicate that five teams had riders tested between 11 PM and 6 AM, a significant deviation from normal testing hours and a rare occurrence in the sport. According to BBC Sport, such tests require "exceptional circumstances," suggesting a need for timely testing in these cases.

Supporters of the night tests, including Jonathan Vaughters, the head of EF-Education Easypost and a former teammate of the infamous Lance Armstrong, argue that these measures are effective in combating micro-dosing of performance-enhancing drugs. Vaughters stated, "Two AM testing is one of the very effective ways to prevent peptide (EPO, HGH) and testosterone micro dosing."

Conversely, the cyclists' union (CPA) has raised concerns about the potential dangers and necessity of waking riders at such hours. However, the UCI (Union Cycliste Internationale) has defended the night tests, emphasizing that the fight against doping remains a top priority. They acknowledged the impact on riders but reiterated that such measures are reserved for justified circumstances.

The International Testing Agency (ITA), responsible for the tests, noted that conducting them during the night is unusual and requires permission from local authorities. While the specific reasons for these tests remain undisclosed, the ITA aims to effectively uphold the integrity of cycling races.

In conclusion, night testing aims to deter micro-dosing practices, which involve ingesting small amounts of drugs that can quickly exit a rider's system. Vaughters emphasized that while inconvenient, such measures could enhance the sport's credibility. As cycling continues to evolve, the balance between rigorous testing and athlete well-being remains a contentious topic.